Takeda and protagonist therapeutics, inc. enter into worldwide license and collaboration agreement for rusfertide, a late-stage rare hematology asset

Takeda will be protagonist's co-development, u.s. co-commercialization partner with 50:50 profit share, and with exclusive ex-u.s. global rights to commercialize rusfertide, protagonist's investigational injectable hepcidin mimetic currently in development for the treatment of polycythemia vera (pv) takeda will make an upfront payment of $300 million at closing partnership combines protagonist's leadership in pharmaceutical peptide drug development with takeda's commercial expertise and 70-plus year legacy of driving innovation within the rare hematology community protagonist to host conference call and webcast today at 4:30 pm et osaka, japan, cambridge, ma, and newark, ca / accesswire / january 31, 2024 / takeda ( tse:4502/nyse:tak ) and protagonist therapeutics, inc., ( nasdaq:ptgx ) today announced the signing of a worldwide license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin, currently in a pivotal phase 3 trial, verify, for the treatment of polycythemia vera (pv). pv is a rare chronic blood disorder characterized by excessive production of red blood cells that affects as many as 160,000 patients in the u.s.[i], with a similar prevalence in europe[ii][iii].
TAK Ratings Summary
TAK Quant Ranking